AG
Artal Group Portfolio holdings
AUM
$930M
1-Year Return
3.57%
This Quarter Return
-9.46%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.4B
AUM Growth
-$664M
(-16%)
Cap. Flow
+$6.27M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
45.82%
Holding
159
New
12
Increased
20
Reduced
9
Closed
8
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
$38.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$29.3M |
| 3 |
Evotec
EVO
|
$27.3M |
| 4 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$27.3M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$26.2M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$172M |
| 2 |
argenx
ARGX
|
$27.1M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
$21M |
| 4 |
Alibaba
BABA
|
$14.8M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$14.1M |
Sector Composition
| 1 | Healthcare | 90.88% |
| 2 | Consumer Discretionary | 7.05% |
| 3 | Materials | 0.52% |
| 4 | Financials | 0.38% |
| 5 | Consumer Staples | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
EQT Corp
EQT
$31.9B
| – | – |
-9,678
| Closed | -$198K |
|
152
Freeport-McMoran
FCX
$66.4B
| – | – |
0
| – | – |
|
153
Intel
INTC
$106B
| – | – |
0
| – | – |
|
154
Merck
MRK
$211B
| – | – |
0
| – | – |
|
155
Olaplex Holdings
OLPX
$1.01B
| – | – |
-225,000
| Closed | -$5.51M |
|
156
Vertex Pharmaceuticals
VRTX
$101B
| – | – |
0
| – | – |
|
157
SPDR S&P Biotech ETF
XBI
$5.36B
| – | – |
0
| – | – |
|
|
DRNA
158
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-700,000
| Closed | -$14.1M |
|
|
XLRN
159
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – |
-1,000,000
| Closed | -$172M |
|